Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

Bordeaux, Aquitaine 33076

7 studies enrolling now · 16 studies all time

What they study most

Advanced/Metastatic Non-Small Cell Lung Cancer, Any Solid Tumor, Biliary Tract Neoplasms, Breast Cancer, Breast Neoplasm, Breast Neoplasms, Cancer of the Prostate, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Colon Cancer, Colorectal Neoplasms, Diffuse Intrinsic Pontine Glioma

Studies at this site

• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) — Recruiting now
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors — Recruiting now
• Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers — Recruiting now
• A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas — Recruiting now
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) — Running, not enrolling
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) — Running, not enrolling
• CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma — Running, not enrolling
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Running, not enrolling
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Running, not enrolling
• Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation — APPROVED_FOR_MARKETING
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors — Running, not enrolling